Healthcare / Medical DevicesKOSDAQ
$22500.00
+600.00 (+2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $25.5B · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$259.2B
P/E
9.2x
↓EV/EBITDA
6.8x
↓ROE
12.1%
↑Gross Margin
40.9%
↓Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.8%
FCF CAGR
+36.4%
FCF margin
14.7%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $173.13B · net income $28.35B · FCF $25.51B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $173.13B | $173.13B | $159.43B | $157.09B | $141.98B |
| Net Income | $28.35B | $28.35B | $28.84B | $26.24B | $15.76B |
| EBITDA | $42.05B | $42.05B | $40.92B | $39.28B | $26.55B |
| EPS | 2457.00 | 2457.00 | 2504.00 | 2278.00 | 1368.00 |
| Gross Margin | 40.9% | 40.9% | 40.0% | 39.8% | 36.0% |
| Operating Margin | 19.2% | 19.2% | 19.2% | 19.0% | 15.5% |
| Net Margin | 16.4% | 16.4% | 18.1% | 16.7% | 11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.16 | 0.17 | 0.20 |
| Current Ratio | 2.53 | 2.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $25.51B | $25.51B | $22.26B | $26.64B | $10.06B |
| Returns | |||||
| ROE | 12.1% | 12.1% | 14.3% | 14.6% | 10.0% |
| Valuation | |||||
| P/E | 9.16 | 9.16 | 7.70 | 12.25 | 15.13 |
| EV/EBITDA | 6.76 | 6.76 | 5.90 | 8.68 | 9.90 |
| P/B | 1.11 | 1.11 | 1.10 | 1.79 | 1.51 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 1.5% | 10.6% | — |
| EPS Growth | -1.9% | -1.9% | 9.9% | 66.5% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-6.7%
EPS terminal req.
$1996.50
Spread vs growth
4.8%
5Y implied EPS CAGR
-0.3%
EPS terminal req.
$2415.77
Spread vs growth
-1.5%
10Y implied EPS CAGR
4.7%
EPS terminal req.
$3890.61
Spread vs growth
-6.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.2%
Start / end P/E
10.5x → 9.2x
EPS bridge
2504.00 → 2457.00
Residual
+0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.